# Regulatory Post-Marketing Surveillance Study for Brolucizumab

> **NCT04985487** · — · RECRUITING · sponsor: **Novartis Pharmaceuticals** · enrollment: 3000 (estimated)

## Conditions studied

- Neovascular Age-related Macular Degeneration

## Interventions

- **OTHER:** brolucizumab

## Key facts

- **NCT ID:** NCT04985487
- **Lead sponsor:** Novartis Pharmaceuticals
- **Sponsor class:** INDUSTRY
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** RECRUITING
- **Start date:** 2021-08-18
- **Primary completion:** 2026-06-14
- **Final completion:** 2026-06-14
- **Target enrollment:** 3000 (ESTIMATED)
- **Last updated:** 2025-01-14


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04985487

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04985487, "Regulatory Post-Marketing Surveillance Study for Brolucizumab". Retrieved via AI Analytics 2026-06-23 from https://api.ai-analytics.org/clinical/NCT04985487. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*